Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Vaxcyte, Inc. | pcvx-ex322_6.htm |
EX-31.2 - EX-31.2 - Vaxcyte, Inc. | pcvx-ex312_8.htm |
EX-31.1 - EX-31.1 - Vaxcyte, Inc. | pcvx-ex311_9.htm |
EX-23.1 - EX-23.1 - Vaxcyte, Inc. | pcvx-ex231_853.htm |
EX-4.2 - EX-4.2 - Vaxcyte, Inc. | pcvx-ex42_374.htm |
10-K - 10-K - Vaxcyte, Inc. | pcvx-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Vaxcyte, Inc. (the “Company”) on Form 10-K for the annual period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or Section15(d) of the Securities Exchange Act of 1934, as amended; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 29, 2021 |
|
By: |
/s/ Grant E.Pickering |
|
|
|
Grant E. Pickering |
|
|
|
Chief Executive Officer |